Premium
Ly49 and CD94/NKG2: developmentally regulated expression and evolution
Author(s) -
Takei Fumio,
McQueen Karina L.,
Maeda Motoi,
Wilhelm Brian T.,
Lohwasser Stefan,
Lian Rebecca H.,
Mager Dixie L.
Publication year - 2001
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1034/j.1600-065x.2001.1810107.x
Subject(s) - biology , microbiology and biotechnology , interleukin 12 , janus kinase 3 , receptor , interleukin 21 , cd8 , cytotoxic t cell , immunology , in vitro , immune system , genetics
Summary: Murine natural killer (NK) cells express two families of MHC class I‐specific receptors, namely the Ly49 family and CD94/NKG2 heterodimers. Stochastic co‐expression of these receptors generates diverse receptor repertoires in adult NK‐cell populations, whereas fetal NK cells have much more limited receptor diversity as they mostly express CD94/NKG2A but not Ly49. These receptors are also expressed on CD8 + T cells and NK1.1 + T cells and regulate their functions, but their expression pattern on NK cells is significantly different from those on T cells. Thus, expression of Ly49 and CD94/NKG2 is developmentally regulated. NK cells acquire the Ly49 family of receptors in an orderly manner as they differentiate from bone marrow progenitors in vitro . Similarly, acquisition of CD94 and NKG2 by NK cells as they differentiate from embryonic stem cells is also orderly. To gain insight into the mechanisms regulating Ly49 expression, potential regulatory regions of several Ly49 genes have been examined. Ly49 genes with different expression patterns have remarkably similar sequences in the putative regulatory regions. Finally, a functional Ly49 gene has been identified in baboon, and primate comparisons suggest that functional extinction of the Ly49 gene in the human lineage seems to have been a relatively recent event. This research was supported by the National Cancer Institute of Canada and the Medical Research Council of Canada with core support from the BC Cancer Agency. KM and BW were supported by studentships from the University of British Columbia and the National Science and Engineering Research Council of Canada. RL is a recipient of a Leukemia Research Fund of Canada fellowship. SL was supported by the Deutsche Forschungsgemeinschaft.